{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:24:33Z","timestamp":1786926273385,"version":"build-2736575974"},"reference-count":143,"publisher":"Elsevier","isbn-type":[{"value":"9780128177402","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2019.02.002","type":"book-chapter","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T13:14:40Z","timestamp":1553174080000},"page":"1-19","source":"Crossref","is-referenced-by-count":85,"title":["Heparin: An essential drug for modern medicine"],"prefix":"10.1016","author":[{"given":"Cui","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/bs.pmbts.2019.02.002_bb0010","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2217\/nnm-2017-0127","article-title":"Heparin: new life for an old drug","volume":"12","author":"Alaez-Verson","year":"2017","journal-title":"Nanomedicine (London)"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2019.02.002_bb0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0167-5273(16)12001-7","article-title":"Heparin centenary\u2014an ever-young life-saving drug","volume":"212","author":"Torri","year":"2016","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0020","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","article-title":"The story of the discovery of heparin and warfarin","volume":"141","author":"Wardrop","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0025","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2741\/4462","article-title":"Heparin and anticoagulation","volume":"21","author":"Onishi","year":"2016","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nbt0310-203","article-title":"Oversulfated chondroitin sulfate is not the sole contaminant in heparin","volume":"28","author":"Pan","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Nat Prod Rep"},{"issue":"30","key":"10.1016\/bs.pmbts.2019.02.002_bb0040","doi-asserted-by":"crossref","first-page":"22966","DOI":"10.1074\/jbc.M109.063735","article-title":"Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways","volume":"285","author":"Pan","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0045","first-page":"1","article-title":"Identification of chemically sulfated\/desulfated glycosaminoglycans in contaminated heparins and development of a simple assay for the detection of most contaminants in heparin","volume":"2010","author":"Pan","year":"2010","journal-title":"Glycobiol Insights"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0050","doi-asserted-by":"crossref","first-page":"xvii","DOI":"10.1016\/S1877-1173(10)93026-3","article-title":"Glycosaminoglycans in development, health and disease. Preface","volume":"93","author":"Zhang","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0055","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/molecules22061025","article-title":"From farm to pharma: an overview of industrial heparin manufacturing methods","volume":"22","author":"van der Meer","year":"2017","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.002_bb0060","first-page":"549417","article-title":"Diversifying the global heparin supply chain: reintroduction of bovine heparin in the United States?","volume":"39","author":"Keire","year":"2015","journal-title":"Pharm Technol"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0065","author":"Administration USDoHaHSFaD"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0070","series-title":"Monograph for Heparin Sodium Heparinum Natricum","author":"European Pharmacopeia","year":"2017"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0075","series-title":"Textbook of Medical Physiology","volume":"vol 464","author":"Guyton","year":"2006"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1877-1173(10)93011-1","article-title":"Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis","volume":"93","author":"Schick","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0085","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/jps.23501","article-title":"Structural characterization of pharmaceutical heparins prepared from different animal tissues","volume":"102","author":"Fu","year":"2013","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/glycob\/cww104","article-title":"Surprising absence of heparin in the intestinal mucosa of baby pigs","volume":"27","author":"Yu","year":"2017","journal-title":"Glycobiology"},{"issue":"suppl 3","key":"10.1016\/bs.pmbts.2019.02.002_bb0095","first-page":"5","article-title":"Production and chemical processing of low molecular weight heparins","volume":"25","author":"Linhardt","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0008-6215(95)00166-Q","article-title":"Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin","volume":"276","author":"Griffin","year":"1995","journal-title":"Carbohydr Res"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1877-1173(10)93001-9","article-title":"Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins","volume":"93","author":"Zhang","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0110","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.3390\/molecules20034254","article-title":"Can we produce heparin\/heparan sulfate biomimetics using \u201cmother-nature\u201d as the gold standard?","volume":"20","author":"Farrugia","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0065-2318(01)57017-1","article-title":"Structure and biological interactions of heparin and heparan sulfate","volume":"57","author":"Casu","year":"2001","journal-title":"Adv Carbohydr Chem Biochem"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.002_bb0125","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1007\/s00216-011-5367-7","article-title":"Structural characterization of heparins from different commercial sources","volume":"401","author":"Zhang","year":"2011","journal-title":"Anal Bioanal Chem"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/brv.12034","article-title":"Glycosaminoglycans in infectious disease","volume":"88","author":"Kamhi","year":"2013","journal-title":"Biol Rev Camb Philos Soc"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1877-1173(10)93008-1","article-title":"Anticoagulant heparan sulfate to not clot\u2014or not?","volume":"93","author":"Shworak","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"45","key":"10.1016\/bs.pmbts.2019.02.002_bb0140","doi-asserted-by":"crossref","first-page":"42311","DOI":"10.1074\/jbc.M101441200","article-title":"6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway","volume":"276","author":"Zhang","year":"2001","journal-title":"J Biol Chem"},{"issue":"31","key":"10.1016\/bs.pmbts.2019.02.002_bb0145","doi-asserted-by":"crossref","first-page":"28806","DOI":"10.1074\/jbc.M100204200","article-title":"The effect of precursor structures on the action of glucosaminyl 3-O-sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate","volume":"276","author":"Zhang","year":"2001","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.002_bb0150","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1074\/jbc.274.9.5681","article-title":"Anticoagulant heparan sulfate precursor structures in F9 embryonal carcinoma cells","volume":"274","author":"Zhang","year":"1999","journal-title":"J Biol Chem"},{"issue":"pt 3","key":"10.1016\/bs.pmbts.2019.02.002_bb0155","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1042\/bj2930849","article-title":"N.m.r. and molecular-modelling studies of the solution conformation of heparin","volume":"293","author":"Mulloy","year":"1993","journal-title":"Biochem J"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.carres.2014.06.023","article-title":"Re-visiting the structure of heparin","volume":"403","author":"Casu","year":"2015","journal-title":"Carbohydr Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0165","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1208\/s12248-017-0047-y","article-title":"A heparin purification process removes spiked transmissible spongiform encephalopathy agent","volume":"19","author":"Bett","year":"2017","journal-title":"AAPS J"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.002_bb0170","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.drudis.2014.07.004","article-title":"Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs","volume":"19","author":"Santos","year":"2014","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0175","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B","article-title":"Heparin-protein interactions","volume":"41","author":"Capila","year":"2002","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0180","series-title":"Essentials of Glycobiology","first-page":"493","article-title":"Proteins that bind sulfated glycosaminoglycans","author":"Esko","year":"2015"},{"issue":"22","key":"10.1016\/bs.pmbts.2019.02.002_bb0185","doi-asserted-by":"crossref","first-page":"19892","DOI":"10.1074\/jbc.M111.228114","article-title":"A systems biology approach for the investigation of the heparin\/heparan sulfate interactome","volume":"286","author":"Ori","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.matbio.2013.11.001","article-title":"Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis","volume":"35","author":"Peysselon","year":"2014","journal-title":"Matrix Biol"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0195","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev-anchem-061010-113911","article-title":"Heparin characterization: challenges and solutions","volume":"4","author":"Jones","year":"2011","journal-title":"Annu Rev Anal Chem (Palo Alto, Calif)"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM197501162920307","article-title":"Actions and interactions of antithrombin and heparin","volume":"292","author":"Rosenberg","year":"1975","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0205","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0006-291X(79)90260-2","article-title":"Highly active heparin species with multiple binding sites for antithrombin","volume":"86","author":"Rosenberg","year":"1979","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0210","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/0006-291X(80)90079-0","article-title":"The interaction of heparin with thrombin and antithrombin","volume":"96","author":"Rosenberg","year":"1980","journal-title":"Biochem Biophys Res Commun"},{"issue":"1\u20133","key":"10.1016\/bs.pmbts.2019.02.002_bb0215","first-page":"351","article-title":"Protease inhibitors of human plasma. Antithrombin-III. \u201cthe heparin-antithrombin system\u201d","volume":"16","author":"Rosenberg","year":"1985","journal-title":"J Med"},{"issue":"18","key":"10.1016\/bs.pmbts.2019.02.002_bb0220","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1016\/S0021-9258(19)43472-8","article-title":"The purification and mechanism of action of human antithrombin-heparin cofactor","volume":"248","author":"Rosenberg","year":"1973","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.002_bb0225","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1073\/pnas.77.11.6551","article-title":"Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin","volume":"77","author":"Lindahl","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0230","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1076029610362071","article-title":"Oversulfated heparin by-products induce thrombin generation in human plasmas through contact system activation","volume":"16","author":"Yi","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0235","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1076029610362072","article-title":"Heparin and oversulfated heparin byproduct induce thrombin generation through contact system activation in plasma of patients with HIT","volume":"16","author":"Yi","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0240","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.immuni.2011.02.008","article-title":"Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo","volume":"34","author":"Oschatz","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0245","doi-asserted-by":"crossref","first-page":"549417","DOI":"10.1155\/2015\/549417","article-title":"Diverse roles of heparan sulfate and heparin in wound repair","volume":"2015","author":"Olczyk","year":"2015","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1242\/dev.121.1.37","article-title":"Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis","volume":"121","author":"Mitsiadis","year":"1995","journal-title":"Development"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0255","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI200113738","article-title":"Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena","volume":"108","author":"Iozzo","year":"2001","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/bs.pmbts.2019.02.002_bb0260","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1002\/pmic.200800042","article-title":"Glycosaminoglycan-binding cytokines as tumor markers","volume":"8","author":"Muramatsu","year":"2008","journal-title":"Proteomics"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0265","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jcp.10030","article-title":"Proteoglycans of the extracellular matrix and growth control","volume":"189","author":"Kresse","year":"2001","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neuron.2005.03.021","article-title":"Sugar codes for axons?","volume":"46","author":"Holt","year":"2005","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0275","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrn1115","article-title":"Extracellular matrix molecules and synaptic plasticity","volume":"4","author":"Dityatev","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1877-1173(10)93019-6","article-title":"Activated contact system and abnormal glycosaminoglycans in lupus and other auto- and non-autoimmune diseases","volume":"93","author":"Weiser","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0285","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1877-1173(10)93014-7","article-title":"Heparin as an inhibitor of cancer progression","volume":"93","author":"Borsig","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0290","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1160\/TH16-08-0620","article-title":"More than an anticoagulant: do heparins have direct anti-inflammatory effects?","volume":"117","author":"Poterucha","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0295","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-0038-1651574","article-title":"Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis","volume":"69","author":"Wakefield","year":"1993","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0300","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1160\/TH11-09-0611","article-title":"Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review","volume":"107","author":"Tichelaar","year":"2012","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0305","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2015-01-624023","article-title":"P-selectin promotes neutrophil extracellular trap formation in mice","volume":"126","author":"Etulain","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0310","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0034-1370765","article-title":"NETosis: a new factor in tumor progression and cancer-associated thrombosis","volume":"40","author":"Demers","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0315","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.matbio.2010.04.003","article-title":"Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer","volume":"29","author":"Casu","year":"2010","journal-title":"Matrix Biol"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.002_bb0320","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1074\/jbc.M512932200","article-title":"Inhibition or activation of Apert syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans","volume":"281","author":"McDowell","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0325","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1159\/000492258","article-title":"Isolation and characterization of a Chinese hamster ovary heparan sulfate cell mutant defective in both met receptor binding and hepatocyte growth factor NK1\/met signaling","volume":"48","author":"Cao","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0330","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd724","article-title":"Novel drug development opportunities for heparin","volume":"1","author":"Lever","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0335","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1172\/JCI1509","article-title":"Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents","volume":"101","author":"Koenig","year":"1998","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0340","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1039\/b100916h","article-title":"Heparin and heparan sulfate: structure and function","volume":"19","author":"Rabenstein","year":"2002","journal-title":"Nat Prod Rep"},{"issue":"27","key":"10.1016\/bs.pmbts.2019.02.002_bb0345","doi-asserted-by":"crossref","first-page":"16160","DOI":"10.1074\/jbc.271.27.16160","article-title":"Single amino acid residues in the E- and P-selectin epidermal growth factor domains can determine carbohydrate binding specificity","volume":"271","author":"Revelle","year":"1996","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0350","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1083\/jcb.130.6.1473","article-title":"Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b\/CD1)","volume":"130","author":"Diamond","year":"1995","journal-title":"J Cell Biol"},{"issue":"6726","key":"10.1016\/bs.pmbts.2019.02.002_bb0355","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/18877","article-title":"Synthesis of thrombin-inhibiting heparin mimetics without side effects","volume":"398","author":"Petitou","year":"1999","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0360","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1054-3589(08)60471-8","article-title":"Heparin in inflammation: potential therapeutic applications beyond anticoagulation","volume":"46","author":"Tyrrell","year":"1999","journal-title":"Adv Pharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0365","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.3390\/molecules20046342","article-title":"Heparin\/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use","volume":"20","author":"Chiodelli","year":"2015","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0370","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1074\/jbc.M510760200","article-title":"VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase","volume":"281","author":"Robinson","year":"2006","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/bs.pmbts.2019.02.002_bb0375","doi-asserted-by":"crossref","first-page":"9818","DOI":"10.1074\/jbc.272.15.9818","article-title":"Interaction of heparin with human angiogenin","volume":"272","author":"Soncin","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0380","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/glycob\/cwg001","article-title":"Glycosaminoglycan structures required for strong binding to midkine, a heparin-binding growth factor","volume":"13","author":"Zou","year":"2003","journal-title":"Glycobiology"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.002_bb0385","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1074\/jbc.272.9.5518","article-title":"Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain","volume":"272","author":"Feyzi","year":"1997","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/bs.pmbts.2019.02.002_bb0390","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1242\/dev.048926","article-title":"HB-EGF function in cardiac valve development requires interaction with heparan sulfate proteoglycans","volume":"137","author":"Iwamoto","year":"2010","journal-title":"Development"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0395","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1097-4644(19991101)75:2<187::AID-JCB1>3.0.CO;2-R","article-title":"Identification of cell-binding site of angiomodulin (AGM\/TAF\/Mac25) that interacts with heparan sulfates on cell surface","volume":"75","author":"Sato","year":"1999","journal-title":"J Cell Biochem"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2019.02.002_bb0400","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0167-5273(16)12004-2","article-title":"Old and new applications of non-anticoagulant heparin","volume":"212","author":"Cassinelli","year":"2016","journal-title":"Int J Cardiol"},{"issue":"52","key":"10.1016\/bs.pmbts.2019.02.002_bb0405","doi-asserted-by":"crossref","first-page":"36535","DOI":"10.1074\/jbc.M109.037267","article-title":"A turn-like structure \u201cKKPE\u201d segment mediates the specific binding of viral protein A27 to heparin and heparan sulfate on cell surfaces","volume":"284","author":"Shih","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0410","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-0-387-71767-8_9","article-title":"Viral heparin-binding complement inhibitors\u2014a recurring theme","volume":"598","author":"Blom","year":"2007","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0415","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.bbrc.2006.07.117","article-title":"Localization of heparin- and neuropilin-1-recognition sites of viral VEGFs","volume":"348","author":"Tokunaga","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0420","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jmb.2005.04.024","article-title":"The oligomeric structure of vaccinia viral envelope protein A27L is essential for binding to heparin and heparan sulfates on cell surfaces: a structural and functional approach using site-specific mutagenesis","volume":"349","author":"Ho","year":"2005","journal-title":"J Mol Biol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0425","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1128\/JVI.70.6.3461-3469.1996","article-title":"Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry","volume":"70","author":"Herold","year":"1996","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.02.002_bb0430","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1073\/pnas.92.8.3546","article-title":"Infection of cells by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin","volume":"92","author":"Zhu","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0435","unstructured":"World Health Organization, WHO Model List of Essential Medicines (19th List), a reprint of the text on the WHO Medicines website: https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/, 2015"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0440","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1586\/17512433.2014.923306","article-title":"Recent advances in antithrombotic treatment for acute coronary syndromes","volume":"7","author":"Howard","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0445","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1525-139X.2006.00177.x","article-title":"The safety of heparins in end-stage renal disease","volume":"19","author":"Sonawane","year":"2006","journal-title":"Semin Dial"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0450","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1525-139X.2010.00770.x","article-title":"Unfractionated heparin for hemodialysis: still the best option","volume":"23","author":"Cronin","year":"2010","journal-title":"Semin Dial"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.002_bb0455","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrneph.2011.88","article-title":"What are the anticoagulation options for intermittent hemodialysis?","volume":"7","author":"Davenport","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0460","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.thromres.2014.03.036","article-title":"Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients","volume":"133","author":"Pon","year":"2014","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.02.002_bb0465","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1093\/ndt\/gft406","article-title":"Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials","volume":"28","author":"Wang","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0470","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5301\/jva.5000183","article-title":"Efficacy of normal saline in the maintenance of the arterial lines in comparison to heparin flush: a comprehensive review of the literature","volume":"15","author":"Kordzadeh","year":"2014","journal-title":"J Vasc Access"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0475","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12882-017-0596-4","article-title":"Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis","volume":"18","author":"Lazrak","year":"2017","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0480","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1160\/TH06-10-0606","article-title":"The management of thrombosis in pregnancy: role of low-molecular-weight heparin","volume":"97","author":"Kher","year":"2007","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0485","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.thromres.2012.01.017","article-title":"Pregnancy-related venous thromboembolism: risk and the effect of thromboprophylaxis","volume":"129","author":"Lussana","year":"2012","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0490","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/bjh.13159","article-title":"The prevention of pregnancy-related venous thromboembolism","volume":"168","author":"Guimicheva","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0495","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0002-9610(70)80023-X","article-title":"Deep vein thrombosis of the leg. Is there a \u201chigh risk\u201d group?","volume":"120","author":"Kakkar","year":"1970","journal-title":"Am J Surg"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0500","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12957-015-0592-8","article-title":"Venous thromboembolism in cancer patients: an underestimated major health problem","volume":"13","author":"Khalil","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"23 suppl 1","key":"10.1016\/bs.pmbts.2019.02.002_bb0505","first-page":"I17","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0510","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1877-1173(10)93020-2","article-title":"Glycosaminoglycans and activated contact system in cancer patient plasmas","volume":"93","author":"Pan","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0515","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/cncr.22892","article-title":"A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications","volume":"110","author":"Kuderer","year":"2007","journal-title":"Cancer"},{"issue":"4612","key":"10.1016\/bs.pmbts.2019.02.002_bb0520","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1126\/science.6192498","article-title":"Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone","volume":"221","author":"Folkman","year":"1983","journal-title":"Science"},{"issue":"19 pt 1","key":"10.1016\/bs.pmbts.2019.02.002_bb0525","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","article-title":"Differential metastasis inhibition by clinically relevant levels of heparins\u2014correlation with selectin inhibition, not antithrombotic activity","volume":"11","author":"Stevenson","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0530","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH05-07-0515","article-title":"The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo","volume":"95","author":"Ludwig","year":"2006","journal-title":"Thromb Haemost"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2019.02.002_bb0535","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S0049-3848(12)70029-4","article-title":"Low-molecular-weight heparin and survival in lung cancer","volume":"129","author":"Noble","year":"2012","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0540","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2006.10.026","article-title":"The anti-inflammatory effects of heparin and related compounds","volume":"122","author":"Young","year":"2008","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0545","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/157016309789869001","article-title":"Therapeutic use of heparin beyond anticoagulation","volume":"6","author":"Ludwig","year":"2009","journal-title":"Curr Drug Discov Technol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0550","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJM199307083290204","article-title":"Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin","volume":"329","author":"Ahmed","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0555","first-page":"507151","article-title":"Anti-inflammatory effects of heparin and its derivatives: a systematic review","volume":"2015","author":"Mousavi","year":"2015","journal-title":"Adv Pharmacol Sci"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0560","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2036.2007.03418.x","article-title":"Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis","volume":"26","author":"Shen","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0565","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1164\/rccm.200612-1803OC","article-title":"Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)","volume":"176","author":"Levi","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0570","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000314853","article-title":"Roles of heparin-binding protein in bacterial infections","volume":"2","author":"Linder","year":"2010","journal-title":"J Innate Immun"},{"issue":"21","key":"10.1016\/bs.pmbts.2019.02.002_bb0575","doi-asserted-by":"crossref","first-page":"11426","DOI":"10.1128\/JVI.01721-13","article-title":"Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16","volume":"87","author":"Richards","year":"2013","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002519","article-title":"Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections","volume":"8","author":"Surviladze","year":"2012","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0585","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/JVI.02190-08","article-title":"Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus","volume":"83","author":"Johnson","year":"2009","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0590","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1128\/JVI.75.3.1565-1570.2001","article-title":"Human papillomavirus infection requires cell surface heparan sulfate","volume":"75","author":"Giroglou","year":"2001","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0595","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.virol.2009.11.011","article-title":"Expanding the role of 3-O sulfated heparan sulfate in herpes simplex virus type-1 entry","volume":"397","author":"O'Donnell","year":"2010","journal-title":"Virology"},{"issue":"18","key":"10.1016\/bs.pmbts.2019.02.002_bb0600","doi-asserted-by":"crossref","first-page":"8970","DOI":"10.1128\/JVI.00296-06","article-title":"Role for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts","volume":"80","author":"Tiwari","year":"2006","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0605","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0092-8674(00)80058-6","article-title":"A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry","volume":"99","author":"Shukla","year":"1999","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0610","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JVI.63.1.52-58.1989","article-title":"Initial interaction of herpes simplex virus with cells is binding to heparan sulfate","volume":"63","author":"WuDunn","year":"1989","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0615","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1083\/jcb.123.3.759","article-title":"A heparin-binding activity on leishmania amastigotes which mediates adhesion to cellular proteoglycans","volume":"123","author":"Love","year":"1993","journal-title":"J Cell Biol"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.02.002_bb0620","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2216","article-title":"Pathways of clathrin-independent endocytosis","volume":"8","author":"Mayor","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"21","key":"10.1016\/bs.pmbts.2019.02.002_bb0625","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1021\/bi800205t","article-title":"Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1","volume":"47","author":"Copeland","year":"2008","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0630","first-page":"43","article-title":"Inhibition of three alphaherpesviruses (herpes simplex 1 and 2 and pseudorabies virus) by heparin, heparan and other sulfated polyelectrolytes","volume":"27","author":"Ramos-Kuri","year":"1996","journal-title":"Arch Med Res"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.02.002_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0020100","article-title":"Release of sequestered malaria parasites upon injection of a glycosaminoglycan","volume":"2","author":"Vogt","year":"2006","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.02.002_bb0640","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit Care Med"},{"issue":"Pt 3","key":"10.1016\/bs.pmbts.2019.02.002_bb0645","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1099\/vir.0.80614-0","article-title":"Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography","volume":"86","author":"Zahn","year":"2005","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0650","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035893","article-title":"The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0655","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-60761-533-0_2","article-title":"New protocol for lentiviral vector mass production","volume":"614","author":"Segura","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0660","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10529-011-0840-0","article-title":"Removing human immunodeficiency virus (HIV) from human blood using immobilized heparin","volume":"34","author":"Nassar","year":"2012","journal-title":"Biotechnol Lett"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0665","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1038\/srep03178","article-title":"Analyses of interactions between heparin and the apical surface proteins of Plasmodium falciparum","volume":"3","author":"Kobayashi","year":"2013","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/pupt.1999.0222","article-title":"Heparin and related molecules as a new treatment for asthma","volume":"13","author":"Diamant","year":"2000","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0675","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/rmed.1999.0677","article-title":"Inhaled heparin is effective in exacerbations of asthma","volume":"94","author":"Bendstrup","year":"2000","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0680","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pupt.2007.08.004","article-title":"Differential responses to various classes of drugs in a model of allergic rhinitis in guinea pigs","volume":"21","author":"Al Suleimani","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.02.002_bb0685","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1165\/ajrcmb.24.5.4315","article-title":"Airway inflammation and bronchial hyperresponsiveness after mycoplasma pneumoniae infection in a murine model","volume":"24","author":"Martin","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.02.002_bb0690","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Lopez-Otin","year":"2013","journal-title":"Cell"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.02.002_bb0695","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cell.2014.10.039","article-title":"Geroscience: linking aging to chronic disease","volume":"159","author":"Kennedy","year":"2014","journal-title":"Cell"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.02.002_bb0700","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1016\/j.transproceed.2003.08.076","article-title":"Antiinflammatory action of heparin via the complement system in renal ischemia-reperfusion","volume":"35","author":"Yagmurdur","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/bs.pmbts.2019.02.002_bb0705","first-page":"119","article-title":"An active fraction of unfractionated heparin from a natural source is recognized by the first component of the complement system","volume":"47","author":"Calabrese","year":"2001","journal-title":"Cell Mol Biol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.02.002_bb0710","first-page":"237","article-title":"The first component of the human complement system recognizes the active fraction of heparin","volume":"43","author":"Calabrese","year":"1997","journal-title":"Cell Mol Biol"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.02.002_bb0715","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0161-5890(93)90079-Q","article-title":"Identification of multiple sites of interaction between heparin and the complement system","volume":"30","author":"Sahu","year":"1993","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.02.002_bb0720","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/s-2008-1066025","article-title":"Survival of heparins, oral anticoagulants, and aspirin after the year 2010","volume":"34","author":"Fareed","year":"2008","journal-title":"Semin Thromb Hemost"}],"container-title":["Progress in Molecular Biology and Translational Science","Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T03:55:52Z","timestamp":1663127752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117319300237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177402"],"references-count":143,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2019.02.002","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}